Optimization of the hydrophobic domain in poly(ethylene oxide)-poly(e{open}-caprolactone) based nano-carriers for the solubilization and delivery of Amphotericin B

Colloids and Surfaces B: Biointerfaces

Volumn 81, Issue 1, 2010, Pages 313-320

  Falamarzian, Arash ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Amphotericin B; Cholesterol; Nano carrier; Poly(ethylene oxide); Poly(e open caprolactone)

Indexed keywords

AMPHOTERICIN B; CAPROLACTONE; HEMOLYTIC ACTIVITY; HYDROPHOBIC DOMAINS; IDENTICAL CONDITIONS; IMPROVED SOLUBILITY; METHOXY; NANOCARRIERS; NANOMETER SIZE RANGE; RED BLOOD CELL; SPHERICAL PARTICLE; STANNOUS OCTOATE; TEM;

BLOOD; CHOLESTEROL; CHROMATOGRAPHIC ANALYSIS; DYNAMIC LIGHT SCATTERING; ETHYLENE; GELS; MONOMERS; NANOPARTICLES; POLYETHYLENE OXIDES; RING OPENING POLYMERIZATION; SOLUBILITY; STRUCTURAL OPTIMIZATION; TRANSMISSION ELECTRON MICROSCOPY;

POLYMERS;

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; DRUG CARRIER; METHOXY POLY(ETHYLENE OXIDE) BLOCK POLY(ALPHA BENZYL EPSILON CAPROLACTONE); METHOXY POLY(ETHYLENE OXIDE) BLOCK POLY(ALPHA CHOLESTERYL CARBOXYLATE EPSILON CAPROLACTONE); METHOXY POLY(ETHYLENE OXIDE) BLOCK POLY(EPSILON CAPROLACTONE); NANOCARRIER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; GEL PERMEATION CHROMATOGRAPHY; HEMOLYSIS; HYDROPHOBICITY; LIGHT SCATTERING; MOLECULAR WEIGHT; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; STRUCTURE ANALYSIS; TRANSMISSION ELECTRON MICROSCOPY;

AMPHOTERICIN B; ANIMALS; CAPSULES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEMOLYSIS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LACTONES; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, CHEMICAL; MOLECULAR STRUCTURE; NANOPARTICLES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

RATTUS;

EID: 77956010490     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2010.07.025     Document Type: Article

References (38)

1. Vakil R., Kwon G.S. Effect of cholesterol on the release of amphotericin B from PEG-phospholilpid micelles. Mol. Pharm. 2008, 5:98-104.
2. Gupta S., Vyas S.P. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. J. Drug Target 2007, 15:206-217.
3. Barwicz J., Dumont I., Ouellet C., Gruda I. Amphotericin B toxicity as related to the formation of oxidatively modified low-density lipoproteins. Biospectroscopy 1998, 4:135-144.
4. Lemke A., Kiderlen A.F., Kayser O. Amphotericin B. Appl. Microbiol. Biotechnol. 2005, 68:151-162.
5. Bang J.Y., Song C.E., Kim C., Park W.D., Cho K.R., Kim P.I., Lee S.R., Chung W.T., Choi K.C. Cytotoxicity of amphotericin B-incorporated polymeric micelles composed of poly(dl-lactide-co-glycolide)/dextran graft co-polymer. Arch. Pharmacal Res. 2008, 31:1463-1469.
6. Brajtburg J., Bolard J. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 1996, 9:512.
7. Aramwit P., Yu B.G., Lavasanifar A., Samuel J., Kwon G.S. The effect of serum albumin on the aggregation state and toxicity of amphotericin B. J. Pharm. Sci. 2000, 89:1589-1593.
8. Torrado J.J., Espada R., Ballesteros M.P., Torrado-Santiago S. Amphotericin B formulations and drug targeting. J. Pharm. Sci. 2008, 97:2405-2425.
9. Yoo B.K., Jalil Miah M.A., Lee E.S., Han K. Reduced renal toxicity of nanoparticular amphotericin B micelles prepared with partially benzylated poly-l-aspartic acid. Biol. Pharm. Bull. 2006, 29:1700-1705.
10. Petrikkos G.L. Lipid formulations of amphotericin B as first-line treatment of zygomycosis. Clin. Microbiol. Infect. 2009, 5(Suppl. 15):87-92.
11. Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 1999, 19:306-323.
12. Boswell G.W., Bekersky I., Buell D., Hiles R., Walsh T.J. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob. Agents Chemother. 1998, 42:263-268.
13. Walsh T.J., Teppler H., Donowitz G.R., Maertens J.A., Baden L.R., Dmoszynska A., Cornely O.A., Bourque M.R., Lupinacci R.J., Sable C.A., dePauw B.E. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. New Engl. J. Med. 2004, 351:1391-1402.
14. Vandermeulen G., Rouxhet L., Arien A., Brewster M.E., Preat V. Encapsulation of amphotericin B in poly(ethylene glycol)-block-poly(epsilon-caprolactone-co-trimethylenecarbonate) polymeric micelles. Int. J. Pharm. 2006, 309:234-240.
15. Vyas S.P., Gupta S. Optimizing efficacy of amphotericin B through nanomodification. Int. J. Nanomed. 2006, 1:417-432.
16. Sedlak M., Pravda M., Kubicova L., Mikulcikova P., Ventura K. Synthesis and characterisation of a new pH-sensitive amphotericin B-poly(ethylene glycol)-b-poly(l-lysine) conjugate. Bioorgan. Med. Chem. Lett. 2007, 17:2554-2557.
17. Moribe K., Maruyama K., Iwatsuru M. Molecular localization and state of amphotericin B in PEG liposomes. Int. J. Pharm. 1999, 193:97-106.
18. Wang C.H., Wang W.T., Hsiue G.H. Development of polyion complex micelles for encapsulating and delivering amphotericin B. Biomaterials 2009, 30:3352-3358.
19. Vakil R., Kwon G.S. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) and PEG-phospholipid form stable mixed micelles in aqueous media. Langmuir 2006, 22:9723-9729.
20. Adams M., Kwon G.S. Spectroscopic investigation of the aggregation state of amphotericin B during loading, freeze-drying, and reconstitution of polymeric micelles. J. Pharm. Sci. 2004, 7:1-6.
21. Adams M.L, Kwon G.S. Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block-poly(N-hexyl-l-aspartamide)-acyl conjugate micelles: effects of acyl chain length. J. Control. Release 2003, 87:23-32.
22. Lavasanifar A., Samuel J., Sattari S., Kwon G.S. Block co-polymer micelles for the encapsulation and delivery of amphotericin B. Pharm. Res. 2002, 19:418-422.
23. Adams M.L., Andes D.R., Kwon G.S. Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(l-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity. Biomacromolecules 2003, 4:750-757.
24. Falamarzian A., Lavasanifar A. Chemical modification of hydrophobic block in poly(ethylene oxide) poly(caprolactone) based nano-carriers: effect on the solubilization and hemolytic activity of amphotericin B. Macromol. Biosci. 2010, 10:648-656.
25. Wasan K.M., Kennedy A.L., Cassidy S.M., Ramaswamy M., Holtorf L., Chou J.W., Pritchard P.H. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 1998, 42:3146-3152.
26. Ramaswamy M, Peteherych K.D., Kennedy A.L., Wasan K.M. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob. Agents Chemother. 2001, 45:1184-1191.
27. Lavasanifar A., Samuel J., Kwon G.S. The effect of alkyl core structure on micellar properties of poly(ethylene oxide)-block-poly(l-aspartamide) derivatives. Colloids Surf. B: Biointerfaces 2001, 22:115-126.
28. Aliabadi H.M., Mahmud A., Sharifabadi A.D., Lavasanifar A. Micelles of methoxy poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. J. Control. Release 2005, 104:301-311.
29. Mahmud A., Patel S., Molavi O., Choi P., Samuel J., Lavasanifar A. Self-associating poly(ethylene oxide)-b-poly(alpha-cholesteryl carboxylate-epsilon-caprolactone) block co-polymer for the solubilization of STAT-3 inhibitor cucurbitacin I. Biomacromolecules 2009, 10:471-478.
30. Mahmud A., Xiong X.B., Lavasanifar A. Novel self-associating poly(ethylene oxide)-block-poly(epsilon-caprolactone) block co-polymers with functional side groups on the polyester block for drug delivery. Macromolecules 2006, 39:9419-9428.
31. Mahmud A., Xiong X.B., Lavasanifar A. Development of novel polymeric micellar drug conjugates and nano-containers with hydrolyzable core structure for doxorubicin delivery. Eur. J. Pharm. Biopharm. 2008, 69:923-934.
32. Lavasanifar A., Samuel J., Kwon G.S. Micelles self-assembled from poly(ethylene oxide)-block-poly(N-hexyl stearate l-aspartamide) by a solvent evaporation method: effect on the solubilization and haemolytic activity of amphotericin B. J. Control. Release 2001, 77:155-160.
33. Elhasi S., Astaneh R., Lavasanifar A. Solubilization of an amphiphilic drug by poly(ethylene oxide)-block-poly(ester) micelles. Eur. J. Pharm. Biopharm. 2007, 65:406-413.
34. Xiong X.B., Uludag H., Lavasanifar A. Biodegradable amphiphilic poly(ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nano-carriers for efficient siRNA delivery. Biomaterials 2009, 30:242-253.
35. Czub J., Neumann A., Borowski E., Baginski M. Influence of a lipid bilayer on the conformational behavior of amphotericin B derivatives-a molecular dynamics study. Biophys. Chem. 2009, 141:105-116.
36. Romero E.A., Valdivieso E., Cohen B.E. Formation of two different types of ion channels by amphotericin B in human erythrocyte membranes. J. Membr. Biol. 2009, 230:69-81.
37. Balakrishnan A.R., Easwaran K.R. Lipid-amphotericin B complex structure in solution: a possible first step in the aggregation process in cell membranes. Biochemistry 1993, 32:4139-4144.
38. Charbonneau C., Fournier I., Dufresne S., Barwicz J., Tancrede P. The interactions of amphotericin B with various sterols in relation to its possible use in anticancer therapy. Biophys. Chem. 2001, 91:125-133.